Sensyne Health signs deal with DHSC on asymptomatic testing
Clinical AI technology firm Sensyne Health has signed a production contract with the Department of Health & Social Care (DHSC) to use Sensyne’s MagnifEye AI technology for reading COVID-19 lateral flow diagnostic tests as part of the UK government’s asymptomatic testing programme.
The scope of this contract with DHSC is for a phased national roll-out over a three-month period in care homes, GP practices and selected private sector organisations with large workforces. Revenues will be shared with Excalibur Health Systems under the terms of the exclusive agreement between the two companies.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: “This is a significant commercial milestone in Sensyne’s development and underlines the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Department of Health & Social Care to support the UK’s national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic.”